UB-221

Phase 1Small molecule

UUnited BioPharma

UB-221 is one of 41 small molecule programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Spontaneous UrticariaActive, not recruiting

Chronic Spontaneous UrticariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Chronic Spontaneous Urticaria

#DrugCompanyPhaseTrials

Claritin

PPerrigo Company

Approved

1 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

4 3

Xolair

Roche

Phase 2

10 4

Bilaxten

MMenarini International Operations Luxembourg SA

Phase 3

1 5

LOU064

Novartis

Phase 3

2 6

Xolair

Roche

Phase 3

1 7

Opzelura

Pfizer

Phase 2

2 8

Barzolvolimab

CCelldex Therapeutics

Phase 3

4 9

Tezspire

AstraZeneca

Phase 2

1 10

Fasenra

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria2 trials

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Unknown status·UUnited BioPharma·Phase 1·NCT04175704·32 enrolled

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Unknown status·UUnited BioPharma·Phase 2·NCT05298215·25 enrolled

Tics1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Completed·UUnited BioPharma·Phase 1·NCT03632291·15 enrolled

Immunogenicity1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Unknown status·UUBP Greater China (Shanghai) Co., Ltd·Phase 1·NCT04404023·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for UB-221. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UB-221 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UB-221. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — United BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUnited BioPharma

UB-221

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Spontaneous Urticaria2 trials

Tics1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News